A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 796 participants.

Also called NCT06034743

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 796 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06034743
  • EU CT 2023-505499-32-00
Other papers using this trial's data
  • Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension The New England journal of medicine, 2025-10-09 DOI, PubMed 40888730, PMC7618089 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Malaysia, Netherlands, Poland, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06034743. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-22 (actual); primary completion 2025-05-21 (actual). Results posted on 2026-07-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Acronym
BaxHTN
Condition
Uncontrolled Hypertension
Condition
Resistant Hypertension
Intervention (Drug)
Baxdrostat
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct06034743
Content hash
89d9a5ec6836f22a1f4b6a90442e5b148a852670e94931eb2bb762c15e1ddb7a